South Rampart Pharma

OUR MISSION

To advance the treatment of pain by developing new, small-molecule solutions that overcome many risks associated with current pain medicines.

OUR DIFFERENCE

Non-Opioid | Lacks Liver Toxicity | Lacks Kidney toxicity

We are developing a novel non opioid without liver and kidney toxicity that is currently in Phase 1 trials

INNOVATION PIPELINE

Broad therapeutic potential, addressing *multiple pain mechanisms & fever*



Phase 1 trial enrollment began in Jan 2022 with topline results in Q3 2022

$30M+	Q1 – Q3 2022	Q4 2022	Q1 - Q4 2023	Q3 2023
Milestone achieved	○ Jan 2022: 1st Ph 1 trial, oral formulation (SAD, MAD, PK) ○ 2nd IND, Neuropathic pain	○ IV formulation Ph 1 (Acute Pain) ○ Ph 1 trial finalized (Q3 2022)— Initiate Ph 2a, 3rd molar extraction	○ 3rd IND, Acute Pain (IV formulation) ○ Phase 2a, Diabetic neuropathic pain ○ Phase 2a Chronic Pain (+/- NIH EPPIC-Net)	○ Ph 1a/b, Acute pain with an IV formulation ○ Liver disease & pain

Clinical Milestones achieved with Series A funding for three pipelines: Acute, neuropathic, and chronic pain

LIFE SCIENCE | Therapeutics, CNS

- Novel Small Molecule
- Non Opioid
- Non Liver & Kidney Toxicity
- Oral and IV Formulations

CLINICAL DEVELOPMENT

Phase 1 Trial Complete Q3 2022

Phase 2-Ready Q4 2022

SOUTH RAMPART PHARMA GLOBAL IP STRATEGY

IP in key world markets

TEAM

Hernan Bazan, MD DFSVS FACS
CEO & Co-founder

Nicolas Bazan, MD PhD
Scientific Co-founder

Robert Dickey, MBA
CFO

Craig Audet, PhD
Dir. Regulatory Affairs & Toxicology

John Wetzel, PhD
Dir. CMC & Formulation

Richard Prince, PhD
Regulatory & Clinical Advisor

FINANCE

$30M
Financing Sought

$7.75M total
Funding to Date

Ph 1 & Ph 2a clinical trials
Use of Funds

Hernan Bazan, **MD DFSVS FACS** – **CEO** & **Co-founder**
Robert Dickey IV, **MBA** – **CFO**
478 Broadway, New Orleans, LA 70118
www.southrampartpharma.com
(504) 444-2882
hbazan@southrampartpharma.com
rdickey@southrampartpharma.com

MECHANISMS OF ACTION

SRP-3D (DA) is a novel small molecule that exerts analgesia (pain reduction) in the **nociception** center of the **brain** through the metabolite **AM404**, a mechanism of action shared with acetaminophen (Tylenol®/Panadol®).

As a **non-opioid**, SRP-3D (DA) will have a ***better safety profile*** than those treatments for pain. Unlike acetaminophen, the leading cause of acute liver failure in the U.S., SRP-3D (DA) does not generate the toxic metabolite NAPQI responsible for ***liver damage*** or disrupt hepatic tight junctions.

Also, it ***does not cause kidney toxicity*** like **NSAIDs**.

As a result, SRP-3D (DA) can reduce both pain and fever without these risks, meeting a critical unmet need.

SRP-3D (DA) reduces pain in four *in vivo* animal pain models, including the *von Frey inflammatory model*, *abdominal writhing*, *tail flick* and the *CFA/Hargreaves inflammatory model and thermal sensitivity studies*. And, it is antipyretic in two fever animal models.





Novel analgesic MOA for lack of hepatotoxicity. **Fragments** encompassing SRP-3D (DA), the novel non-opioid and non-liver toxic analgesic asset. The **MOA** for the lack of liver toxicity compared to acetaminophen is because it does not produce **NAPQI** nor disrupts **hepatic tight junctions**. Two representative in vivo models for the pain relief, acetic acid writhing and CFA/von Frey with electronic detection.

PATHWAY TO CLINICAL DEVELOPMENT



Following incubation of the pre-clinical development of the novel non-opioid and non-hepatotoxic lead asset SRP-3D (DA) in the co-founders' laboratories, two seed investments and an NIH STTR 'fast-track' totaling $7.75M have allowed the first Ph 1 trial in Q1 2022 and development of multiple pain pipelines